Zealand Pharma Introduces Metabolic Frontier 2030 Plan at Morgan Stanley Conference: Five Commercial Products by 2030 Anchored on Petrelintide Roche Partnership
Zealand Pharma (NASDAQ: ZLDPY; Copenhagen: ZEAL) CEO Adam Steensberg presented Wednesday September 16, 2026 at 11:30 a.m. EDT at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, introducing the company's Metabolic Frontier 2030 strategic plan targeting five commercial products by 2030. The plan anchors on petrelintide (long-acting subcutaneous amylin analog Phase 3 with Roche under an April 2026 exclusive collaboration and licensing agreement; deal terms up to $5.3 billion including $1.65 billion upfront, plus 50/50 profit share on both monotherapy and combination products including petrelintide plus Roche's enicepatide GLP-1/GIP dual agonist). Phase 2 ZUPREME-1 documented up to 10.7% mean weight loss at 42 weeks versus 1.7% placebo, with no vomiting cases and no GI-related discontinuations at the maximally effective dose. Steensberg indicated the next phase of obesity competition may center on tolerability and patient retention rather than only on weight-loss magnitude — a positioning that differentiates petrelintide from the higher-efficacy but higher-GI-burden retatrutide (28% weight loss) and CagriSema. Zealand is building integrated commercial capabilities for petrelintide while relying on partners for other assets in rare disease and inflammation.